시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 생식샘자극호르몬 분비 호르몬(GnRH) 수용체 길항제 시장 보고서(2025년)
Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Global Market Report 2025
상품코드 : 1810902
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,394,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,242,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,090,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

생식샘자극호르몬 분비 호르몬(GnRH) 수용체 길항제 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년에는 22억 달러로 성장하여 CAGR 8.5%를 보일 것입니다. 예측 기간 동안 성장에 기여하는 요인으로는 표적 맞춤형 의약품의 채택 증가, 신흥 시장에서 수요 증가, 여성 생식 기능 장애에 대한 관심 증가, 외래 치료 옵션으로의 전환, 양호한 결과를 가져오는 임상 검사 증가 등이 있습니다. 이 기간의 주요 동향으로는 비용 효율성 향상을 위한 바이오시밀러 개발, 약물 치료와 병행하는 디지털 치료의 통합, 다제 병용 암 치료로의 통합, 선택성을 높이기 위한 분자 설계의 발전, 소아 및 청소년 환자를 대상으로 한 혁신 등이 있습니다.

호르몬 관련 질환의 유병률 증가는 향후 몇 년 동안 생식샘자극호르몬 분비 호르몬(GnRH) 수용체 길항제 시장의 성장을 견인할 것으로 예측됩니다. 호르몬 관련 질환은 호르몬의 생산, 분비, 작용의 불균형이나 기능 장애로 인해 발생하는 병적 상태를 말하며, 대사, 성장, 생식, 기분 등의 과정에 영향을 미칩니다. 이러한 증가는 식습관, 운동부족, 스트레스, 수면장애 등 호르몬 균형에 악영향을 미치는 생활습관에 기인하는 바가 큽니다. GnRH 수용체 길항제는 성선자극호르몬 분비 호르몬 수용체를 직접 차단하여 질환의 진행에 기여하는 성호르몬의 생성을 감소시킵니다. 예를 들어, 2025년 2월 세계보건기구(WHO)는 다낭성 난소 증후군이 가임기 여성에게 가장 흔한 호르몬 이상 중 하나이며, 연간 약 6-13%의 여성이 앓고 있으며, 최대 70%가 진단되지 않은 채로 남아 있다고 보고했습니다. 그 결과, 호르몬 관련 질환 증가로 생식샘자극호르몬 분비 호르몬(GnRH) 수용체 길항제 시장이 성장하고 있습니다.

GnRH 수용체 길항제 시장의 주요 기업들은 다양한 환자들의 요구를 충족시키고 여성 건강의 치료 결과를 개선하기 위해 호르몬 대체 요법을 병행하거나 병행하지 않는 유연한 경구 투여 옵션과 같은 진보된 치료법을 개발하고 있습니다. 유연한 경구 투여가 가능해짐에 따라 맞춤 치료 계획이 가능해져 환자는 장기 사용을 위한 호르몬 보조요법으로 자궁근종 증상을 관리하거나, 호르몬 요법을 사용할 수 없는 환자에게 대체 요법을 제공함으로써 호르몬 없이도 자궁근종 증상을 관리할 수 있게 되었습니다. 예를 들어, 2022년 6월 스위스 바이오 제약사 ObsEva SA는 영국 제약사 Theramex와 공동으로 EU에서 승인된 1일 1회 경구용 GnRH 길항제 Yselty(린자고릭스)를 출시하였습니다. 이 치료에는 몇 가지 투여 방법이 있습니다. 100mg 또는 200mg을 호르몬 요법과 병용하여 제한 없이 사용하는 방법, 100mg을 호르몬 요법 없이 사용하는 방법, 200mg을 자궁근종 양의 감소가 임상적으로 필요한 경우 단기간 사용하는 방법입니다. 이러한 유연한 요법은 월경 과다 출혈과 자궁 크기를 줄이는 것을 목표로 하며, 중등도에서 중증의 자궁근종 증상에 대한 비수술적 대안을 제시합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 코로나재난과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 전략

제36장 부록

LSH
영문 목차

영문목차

Gonadotropin-releasing hormone (GnRH) receptor antagonists are a group of drugs that work by blocking GnRH receptors in the pituitary gland. By doing so, they inhibit the release of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which stimulate sex hormone production in the gonads.

The main categories of GnRH receptor antagonists include peptide-based and non-peptide-based antagonists. Peptide GnRH receptor antagonists are synthetic peptides that block these receptors in the pituitary, quickly reducing LH and FSH levels to treat hormone-dependent conditions. These medications can be administered orally, by injection, or through the skin (transdermal). They are used in a range of patient groups, including adult men, adult women, and children. Common therapeutic applications include prostate cancer, breast cancer, endometriosis, uterine fibroids, and precocious puberty. These drugs are distributed via hospital pharmacies, retail pharmacies, online pharmacies, and other channels.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The gonadotropin-releasing hormone (GnRH) receptor antagonists market research report is one of a series of new reports from The Business Research Company that provides gonadotropin-releasing hormone (GnRH) receptor antagonists market statistics, including gonadotropin-releasing hormone (GnRH) receptor antagonists global market size, regional shares, competitors with gonadotropin-releasing hormone (GnRH) receptor antagonists market share, detailed gonadotropin-releasing hormone (GnRH) receptor antagonists market segments, market trends and opportunities, and any further data you may need to thrive in the gonadotropin-releasing hormone (GnRH) receptor antagonists industry. The gonadotropin-releasing hormone (GnRH) receptor antagonists market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gonadotropin-releasing hormone (GnRH) receptor antagonists market size has grown strongly in recent years. It will grow from $1.46 billion in 2024 to $1.59 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. Growth during the historic period was driven by the rising incidence of prostate and breast cancers, heightened awareness of hormone-dependent diseases, an increased emphasis on minimally invasive treatments, expanded government support for reproductive health, and growing investments in oncology drug development.

The gonadotropin-releasing hormone (GnRH) receptor antagonists market size is expected to see strong growth in the next few years. It will grow to $2.20 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. Growth in the forecast period is expected to be fueled by increasing adoption of targeted and personalized medicines, rising demand in emerging markets, greater focus on female reproductive health disorders, a shift toward outpatient treatment options, and a growing number of clinical trials with positive results. Key trends during this period include the development of biosimilars to improve cost-effectiveness, the integration of digital therapeutics alongside drug treatments, incorporation into multimodal cancer therapies, advances in molecular design for enhanced selectivity, and innovations targeting pediatric and adolescent patient use.

The growing prevalence of hormone-related disorders is expected to drive the expansion of the gonadotropin-releasing hormone (GnRH) receptor antagonists market in the coming years. Hormone-related disorders are medical conditions caused by imbalances or dysfunctions in hormone production, secretion, or action, affecting processes like metabolism, growth, reproduction, and mood. This increase is largely attributed to lifestyle factors such as poor diet, lack of exercise, stress, and disrupted sleep, all of which can negatively affect hormonal balance. GnRH receptor antagonists work by directly blocking gonadotropin-releasing hormone receptors, thereby lowering the production of sex hormones that contribute to disease progression. For example, in February 2025, the World Health Organization reported that polycystic ovary syndrome, one of the most common hormonal disorders in women of reproductive age, affects approximately 6-13% of women annually, with up to 70% of cases remaining undiagnosed. As a result, the rise in hormone-related disorders is boosting the gonadotropin-releasing hormone (GnRH) receptor antagonists market.

Key players in the GnRH receptor antagonist market are developing advanced therapies such as flexible oral dosing options, with and without hormonal add-back therapy, to meet diverse patient needs and improve treatment outcomes in women's health. The availability of flexible oral dosing enables personalized treatment plans, allowing patients to manage uterine fibroid symptoms with hormonal support for long-term use or without hormones, providing alternatives for those who cannot use hormonal therapy. For instance, in June 2022, ObsEva SA, a Switzerland-based biopharmaceutical company, in collaboration with Theramex, a UK-based pharmaceutical firm, launched Yselty (linzagolix), a once-daily oral GnRH antagonist approved in the European Union. This therapy offers several dosing options: 100 mg or 200 mg with hormonal therapy for unrestricted use, 100 mg without hormonal therapy for women avoiding hormones, and 200 mg for short-term use when reducing fibroid volume is clinically necessary. These flexible regimens aim to decrease heavy menstrual bleeding and uterine size, providing a non-surgical option for moderate to severe uterine fibroid symptoms.

In June 2025, Knight Therapeutics Inc., a Canadian pharmaceutical company, formed a partnership with Sumitomo Pharma America Inc. The collaboration seeks to commercialize key specialty medicines from Sumitomo Pharma, including Myfembree, Orgovyx, and Vibegron, in Canada, while also acquiring additional mature products to strengthen its portfolio and market presence. Sumitomo Pharma Co., Ltd., based in Japan, is a multinational pharmaceutical company that develops and markets oral GnRH receptor antagonists used to treat prostate cancer, uterine fibroids, and endometriosis.

Major players in the gonadotropin-releasing hormone (gnrh) receptor antagonists market are Pfizer Inc, AbbVie Inc., Bayer AG, Novartis AG, Takeda Pharmaceutical Company Limited., Merck KGaA, Astellas Pharma Inc., Intas Pharmaceuticals Ltd., Organon And Co., Sun Pharmaceutical Industries Ltd., Jiangsu Hengrui Medicine Co. Ltd., Dr. Reddy's Laboratories Ltd., Zydus Lifesciences Limited., Gland Pharma Limited., Bachem Holding AG, Kissei Pharmaceutical Co. Ltd., Myovant Sciences GmbH, Ferring International Center S.A., Theramex HQ UK Limited, Veru Inc.

North America was the largest region in the gonadotropin-releasing hormone (GnRH) receptor antagonists receptor antagonists market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gonadotropin-releasing hormone (GnRH) receptor antagonists report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gonadotropin-releasing hormone (GnRH) receptor antagonists market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gonadotropin-releasing hormone (GnRH) receptor antagonists market consists of sales of as abarelix, tezarelix, razarelix, and ozarelix. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gonadotropin-releasing hormone (gnrh) receptor antagonists market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for gonadotropin-releasing hormone (gnrh) receptor antagonists ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gonadotropin-releasing hormone (gnrh) receptor antagonists market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market Characteristics

3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market Trends And Strategies

4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Growth Analysis And Strategic Analysis Framework

6. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market Segmentation

7. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market Regional And Country Analysis

8. Asia-Pacific Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market

9. China Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market

10. India Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market

11. Japan Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market

12. Australia Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market

13. Indonesia Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market

14. South Korea Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market

15. Western Europe Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market

16. UK Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market

17. Germany Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market

18. France Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market

19. Italy Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market

20. Spain Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market

21. Eastern Europe Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market

22. Russia Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market

23. North America Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market

24. USA Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market

25. Canada Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market

26. South America Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market

27. Brazil Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market

28. Middle East Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market

29. Africa Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market

30. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market Competitive Landscape And Company Profiles

31. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market Other Major And Innovative Companies

32. Global Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market

34. Recent Developments In The Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market

35. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonists Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기